Welcome to our dedicated page for Veri Medtech Holdings SEC filings (Ticker: VRHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Veri Medtech Holdings, Inc. (VRHI) SEC filings page on Stock Titan is designed to surface the company’s regulatory disclosures as they become available from the U.S. Securities and Exchange Commission. Veri Medtech has announced that it filed a registration statement on Form S-1 for a proposed initial public offering of its Class A common stock, and future SEC filings will provide additional detail on its healthcare technology business, risk factors, and capital structure.
As a publicly traded healthcare technology and telemedicine company, Veri Medtech’s key filings are expected to include annual reports on Form 10-K and quarterly reports on Form 10-Q, once available. These documents typically describe business operations such as its proprietary healthcare technology platform, alternative medicine and wellness services, and subsidiaries like Veriheal and DosePop. They also generally include discussions of telehealth infrastructure, diagnostic intelligence, and other elements the company highlights in its public communications.
Stock Titan enhances access to these filings with AI-powered summaries that help explain complex sections in plain language. When Forms 10-K, 10-Q, and other reports such as Form 8-K or proxy statements are filed, the platform can highlight important disclosures related to revenue models, patient and physician networks, acquisitions of complementary healthcare companies, and risk considerations.
In addition, insider transaction reports on Form 4, when filed, can be viewed to track purchases and sales by Veri Medtech officers, directors, or major shareholders. Real-time updates from EDGAR combined with AI-generated insights allow users to quickly review the most relevant aspects of VRHI’s regulatory history without manually reading every page of each filing.
Veri Medtech Holdings, Inc. is pursuing a primary firm commitment public offering of common stock to move its listing from the OTC market to the NYSE American, with net proceeds intended for organic and acquisitive growth. The company operates a healthcare technology platform, primarily through subsidiary Veriheal, that helps patients obtain medical marijuana cards and related consultations across numerous U.S. states. Veri Medtech generated approximately $22 million in revenue in 2023 and $17 million in 2024, shifting from about $3.53 million of net income in 2023 to a net loss of roughly $409,000 in 2024. As of December 31, 2024 and September 30, 2025, it reported shareholders’ and working capital deficits and recent net losses, and its auditors highlight substantial doubt about its ability to continue as a going concern without additional capital.